Remote pre-exposure prophylaxis adherence monitoring among young, Black men who have sex with men: a feasibility and acceptability pilot study
Jones et al.
The finding, in our words
The study determined that using self-collected dried blood spots alongside online surveys was a feasible and acceptable method for remote pre-exposure prophylaxis adherence monitoring, with 64% of participants returning at least one blood specimen.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
In adult kidney transplant patients, adding DBS home sampling to usual care did not reduce outpatient visits or per-visit costs versus usual care alone, though most patients were willing to use DBS if it cut hospital attendances; logistical optimisation of mailing and timely analysis is required to realise travel and cost benefits.
This review found that volumetric microsampling devices, such as Mitra, HemaPEN, HemaXis DB10, and Tasso-M20, overcome haematocrit bias, whilst Telimmune plasma separation cards enable direct plasma collection without centrifugation. These technologies support patient-centric, decentralised sampling, though the authors note that clinical validation remains limited across different drugs and patient populations.
The study found that although participants preferred patient-centric microsampling devices for home use, the agreement with venous plasma for measuring CRP and cytokines was inconsistent, indicating that further validation is required before these methods replace standard venipuncture.
In a pilot mixed-methods study of youth with HIV, mailed HemaSpot-HF kits enabled home-based dried blood spot collection that participants found feasible and acceptable, supporting remote viral load monitoring and a self-management model for decentralised care.
The study found that quantitative dried blood spot sampling provided high clinical agreement for tacrolimus and creatinine monitoring, with patients rating the self-collection devices as user-friendly. These results support the feasibility of decentralised therapeutic drug monitoring for immunosuppressants.